Material Event Form 8 K

Item 8.01 Other Events

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals, Inc. (the "Company") reports groundbreaking preclinical results confirming the efficacy of Telomir-1, its licensed compound designed to effectively turn back the biological clock and support longevity

Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrated significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline.

By addressing the biological drivers of aging, Telomir-1 has the potential to profoundly impact patient care, offering new hope for managing and reversing age-related diseases while improving quality of life for countless individuals.

Study Summary and Methodology

The preclinical study, conducted in collaboration with Nagi Bioscience SA, utilized a sophisticated in vivo microfluidic-based assay to assess the effects of Telomir-1 on the nematode Caenorhabditis elegans, a well-established model for aging studies. The microfluidic platform allowed precise, automated tracking of lifespan, healthspan, and age-related mobility decline in real-time, enabling the research team to accurately measure the effects of Telomir-1 on these critical metrics. Two forms of Telomir-1 were administered in two concentrations, allowing the study to examine dose-dependent responses in treated subjects. The study found that Telomir-1 significantly enhanced lifespan and healthspan parameters in aged microorganism populations.

Key findings included:

	●	Enhanced Mobility in Older Organisms: Subjects treated with Telomir-1 showed improved motility, particularly in later stages of life, compared to untreated controls. This enhanced movement in advanced age suggests a slowing of the aging process, as mobility is a key indicator of biological health.
	●	Reduced Biological Aging: The study demonstrated a measurable reversal of biological age markers in subjects treated with Telomir-1. This significant finding points to Telomir-1's potential to slow down, and in certain aspects, reverse biological aging, making it a promising candidate for longevity treatments.
	●	Increased Lifespan: Telomir-1 was associated with a statistically significant increase in lifespan among treated populations. This further supports Telomir-1's role in promoting longevity.

Expanding Research and Future Applications

The Company is intensifying its focus on the potential use of Telomir-1 to treat progeria, a rare genetic disorder that causes accelerated aging in children. As part of these efforts, the Company has engaged with the Progeria Foundation to investigate the effects of Telomir-1 on human progeria cell lines. This study will directly assess Telomir-1's ability to counteract accelerated aging at the cellular level, offering critical insights into its therapeutic potential for progeria patients.

Public link

Please use the above public link if you want to share this noodl on another website.